

wherein R¹, R², R³, and R⁴ are the same or different and are each a hydrogen atom or a lower alkyl group, R⁵ is a hydrogen atom, a lower alkyl group, or a lower acyl group, X is a monosaccharide residue or an oligosaccharide residue optionally having a lower alkyl group or a lower acyl group substitute for the hydrogen atom of the hydroxyl group in the saccharide residue, n is an integer in the range of 0-6, and m is an integer in the range of 1-6.

6. (New) The method of claim 5 wherein said chromanol glucoside is 2-(α -D-glucopyranosyl)methyl-2,5,7,8-tetramethylchroman-6-ol.

7. (New) The method of claim 5 wherein said arteriosclerosis is atherosclerosis.


~~8. (New) The method of claim 1 wherein said agent is an aqueous preparation.~~

9. (New) The method of claim 5 wherein the agent is administered orally.

10. (New) The method of claim 5 wherein the agent is administered non-orally.

REMARKS

Claims 3 and 4 have been amended. Claims 5-10 have been added. Attached is a clean copy of claims 3-10. Claims 1-10 are in this application.

Claims 3 and 4 have been amended to cancel multiple dependencies. Applicants believe that the claims would have been allowable as originally filed. Accordingly, applicants assert that no claims have been narrowed within the meaning of the Federal Circuit's recent decision in *Festo Corp. v. Shoketsu Kinzoku Kohyo Kabushiki Co.*, No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).

A prompt and favorable action on the merits is earnestly solicited. It is believed that no fee is required. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 13-2165.